IL17A and Stroke: The presence of IL-17A in the brain area after stroke makes BM-MSCs a very good candidate for stem cell therapy, even if it will be interesting to investigate if another type of stem cell retains the same potential or, maybe, a different choice of stem cells could result in a faster or more efficient neuronal differentiation in neurons even faster or more efficiently.